Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Influenza Vaccines Market Valued at Present and by 2029?

In recent times, the influenza vaccines market size has seen robust growth. The market, which is set to expand from $8.5 billion in 2024 to $9.04 billion in 2025, will have a compound annual growth rate (CAGR) of 6.3%. A few contributing factors to this growth during the historic period have been the readiness for pandemics, initiatives in public health, studies on the effectiveness of vaccines, recommendations from healthcare professionals, and worldwide surveillance of influenza.

Strong expansion is anticipated in the influenza vaccines market in the upcoming years. The market is predicted to ascend to “$12.13 billion in 2029, experiencing a compound annual growth rate (CAGR) of 7.6%. The projected growth during this period can be ascribed to factors such as climate and environmental changes, enhancements in healthcare accessibility, the emergence of new influenza strains, adjuvants and delivery systems innovations, and an increase in healthcare spending. Forecast trends include the broader application of mRNA vaccine technology, a concentration on pediatric immunization, measures to control seasonal influenza, improved vaccination coverage in underdeveloped countries, and custom vaccination strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

#What Drivers Are Influencing Growth In The Influenza Vaccines Market?

The influenza vaccine market’s expansion is anticipated to be spurred by increasing occurrences of seasonal influenza. This respiratory illness, typically rampant during certain periods of the year, especially the colder months, is brought about by influenza viruses. The emergence of this shift can be attributed to antigenic drift, environmental factors, population vulnerability, suboptimal vaccine coverage, and an absence of universal vaccination. Influenza vaccines play a crucial role in decreasing the incidents of seasonal influenza by providing immunity against the active strains of the virus. For instance, the US government agency, the Centers for Disease Control and Prevention (CDC), in November 2023, revealed that there were roughly 31 million instances of flu-related illnesses, 14 million flu-related clinical visits, 360,000 flu-related hospital stays, and 21,000 flu-related fatalities during the 2022-2023 flu season. Consequently, the escalating occurrences of influenza seasons are fuelling the growth of the influenza vaccines market.

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

What Trends Are Currently Influencing Growth In The Influenza Vaccines Market?

The growing trend of utilizing cutting-edge technologies for vaccine production has been observed in the influenza vaccine market. To maintain their market stance, firms involved in influenza vaccine production are embracing these advanced manufacturing techniques. Take for example GlaxoSmithKline PLC., a pharmaceutical and biotechnology firm based in the UK, which initiated the Multiple Antigen Presenting System (MAPS) for vaccine creation in January 2023. This pioneering technique offers a new approach to build potent vaccines against bacteria and viruses. It can be particularly effective for swift vaccine development during outbreaks of epidemics or pandemics.

Which Companies Play A Key Role In The Development Of The Influenza Vaccines Market?

Major companies operating in the influenza vaccines market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

What Are The Key Regional Developments Shaping The Influenza Vaccines Market?

North America was the largest region in the influenza vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11935&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model